KBP2000-articles. [Five year survival for lung cancer patients managed in general hospitals]
|
|
- Rodney Whitehead
- 6 years ago
- Views:
Transcription
1 1. Rev Mal Respir Jan;26(1): KBP2000-articles [Five year survival for lung cancer patients managed in general hospitals] Grivaux M, Zureik M, Marsal L, Asselain B, Peureux M, Chavaillon JM, Prud'homme A, Carbonnelle M, Goarant E, Maury B, Bedossa A, Blanchon F. Service de Pneumologie, Hôpital de Meaux, France. INTRODUCTION: In 2000 the College of Pulmonologists of General Hospitals undertook an epidemiological study (KBP-2000-CPHG) enrolling all new cases of histologically confirmed lung cancer managed in general hospitals. This paper reports the five year survival in these cases. METHODS: Vital status was available for 5447 out of 5667 patients included in the original study. The effect of different prognostic factors on mortality was assessed. RESULTS: At 5 years 567 patients (10.4%) were still alive. Median survival for the 4880 (89.6%) deceased patients was 7 months. Univariate analysis identified age, smoking history, performance status, histological type and disease stage (TMN classification) as determinants of survival. For non-small cell lung cancer (n=4885) multivariate analysis identified five predictive factors for mortality - age, gender histological type, performance status and stage. CONCLUSIONS: Five year survival in lung cancer continues to be poor. As the risk factors for poor outcome at the time of diagnosis are not modifiable and pending the results of screening studies reduction in mortality must rest on primary prevention. PMID: [PubMed - indexed for MEDLINE] 2. Lancet Oncol Oct;7(10): year mortality in patients with non-small-cell lung cancer: development and validation of a prognostic index. Blanchon F, Grivaux M, Asselain B, Lebas FX, Orlando JP, Piquet J, Zureik M. Service de Pneumologie, Centre Hospitalier de Meaux, Meaux, France. Comment in: Lancet Oncol Oct;7(10): BACKGROUND: Lung cancer is the commonest cause of death due to cancer in the world. Non-small-cell lung carcinoma (NSCLC) represents about 80% of overall lung cancer cases worldwide. An accurate predictive model of mortality in patients with NSCLC could be useful to clinicians, policy makers, and researchers involved in risk stratification. The objective of this study was to develop and validate a simple prognostic index for 4-year mortality in patients with NSCLC by use of information obtained at the time of lung cancer diagnosis. METHODS: In 2000, 4669 patients with histologically or cytologically proven NSCLC were enrolled prospectively from 137 pneumology departments in French general hospitals. Patients not lost to follow-up (n=4479) were randomly assigned to the development cohort (n=2979) or the validation cohort (n=1500). Every patient's physician completed a standard and anonymous questionnaire. We used a Cox model to identify variables independently associated with mortality and weighted the variables to create a prognostic index. FINDINGS: Median follow-up for survivors was 49 months (IQR 46-51). There were 2585 deaths (87%) in the development cohort and 1310 deaths (87%) in the validation cohort. Five independent predictors of mortality Page 1
2 were identified: age (>70 years, 1 point); sex (male, 1 point); performance status at diagnosis (reduced activity, 3 points; active >50%, 5 points; inactive >50%, 8 points; and total incapacity, 10 points); histological type (large-cell carcinoma, 2 points); and tumour-node-metastasis (TNM) staging system (IIA or IIB, 3 points; IIIA or IIIB, 6 points; and IV, 8 points). The minimum and maximum possible point scores were 0 and 22, respectively. Scores of the prognostic index were strongly associated with 4-year mortality in the development cohort: 0-1 points predicted a 35% (95% CI 28-43) risk, 2-4 points a 59% (52-66) risk, 5-7 points a 77% (72-81) risk, 8-10 points an 88% (85-90) risk, points a 97% (96-98) risk, and points a 99% (97-100) risk. The corresponding percentages in the validation cohort were 36% (24-47), 60% (50-70), 77% (71-83), 89% (86-93), 96% (95-98), and 99% (98-100), respectively. The prognostic index showed good discrimination, with mean bootstrap c statistics of 0.85 (95% CI ) in the development cohort and 0.86 (95% CI ) in the validation cohort. INTERPRETATION: This prognostic index, incorporating personal, tumour, and functional information would be helpful in guiding patient management, resource use, and the design of clinical trials. PMID: [PubMed - indexed for MEDLINE] 3. Rev Mal Respir Apr;23(2 Pt 1): [Cohort KBP-2000-CPHG: Evaluation of factors influencing survival in lung cancer] Blanchon F, Grivaux M, Zureik M, Marsal L, Asselain B, Lebas FX, Orlando JP, Steenhouwer F, Benichou-Flurin M, Coëtmeur D, Collon T, David P, Delclaux B, Piquet J. Service de pneumologie, Hôpital de Meaux, France. f-blanchon@ch-meaux.fr Comment in: Rev Mal Respir Apr;23(2 Pt 1): INTRODUCTION: Lung cancer continues to have a poor prognosis despite some therapeutic advances. BACKGROUND: The last fifteen years has seen a dramatic increase in the incidence of lung cancer in women and an increased proportion of adenocarcinomas in both sexes. A study of overall survival as a function of gender and other prognostic factors has been established using the cohort of patients from the study KBP-2000-CPHG. METHODS: KBP-2000-CPHG is an epidemiological study carried out throughout the year 2000 looking at histologically confirmed primary lung cancers managed in general hospitals. 5,667 patients have been included. The study of survival looks at 2 and 5-year outcomes. The date and cause of death are recorded for each patient. In the absence of these data the date of the last contact is noted. If this is less than 4 months the patient is considered to be alive. If more than four months have elapsed a graduated strategy for establishing vital status is pursued which involves reviewing records from various different sources. RESULTS AWAITED: A preliminary review of the data was undertaken between September 2004 and March 2005 which obtained data on patients. The analysis of survival according to sex and other forecast prognostic factors is underway. PMID: [PubMed - indexed for MEDLINE] 4. Rev Mal Respir Nov;21(5 Pt 3):8S70-8. Page 2
3 [Primary lung cancer in elderly subjects in France] Piquet J, Blanchon F, Grivaux M, Collon T, Zureik M, Barbieux H, Bénichou-Flurin M, Breton JL, Coëtmeur D, Delclaux B, Braun D, Homasson JP, Mouysset F, Riou R, le Poulain-Doubliez M, Marsal L; CPHG. Hôpital, Le Raincy-Montfermeil, France. INTRODUCTION: There are few data on primary bronchial carcinoma in France. We report here the results of the study KBP 2000-CPHG in which there were 1868 patients aged 70 or more and 338 aged 80 or more. METHODS: We compared the patients under 70 (Group I) with those aged 70 or more (Group II) as well as with the details of the over 80's. RESULTS: Group II included significantly more women (17.4% vs 15.2%; p = 0.04), non-smokers (11.2% vs 5.3%; p<0.0001), patients of poor performance status (24.2% vs 14.5%; p<0.0001) and squamous carcinomas (44.5% vs 37.8%; p<0.001) than Group I, but fewer adenocarcinomas (27.2% vs 31.5%; p = 0.009) and as many small cell carcinomas (15.9% vs 16.9%; p = 0.32). In Group II there were less stage III and IV tumours (75.1% vs 78.1%; p = ) more symptomatic treatment (23.2% vs 6.1%) and radiotherapy alone (12.8% vs 3.8%; p < ). The results were similar beyond 80 years. On multivariate analysis age, performance status and stage appeared to be independent variables in the choice of curative or symptomatic treatment. CONCLUSIONS: Age alone is not therefore a limiting factor in the choice of treatment. PMID: [PubMed - indexed for MEDLINE] 5. Rev Pneumol Clin Dec;60(6 Pt 1): [Primary non-small-cell lung cancer: analysis of 419 T1 (<or=3 cm) tumors in the KBP-2000-CPHG study] Collon T, Ba O, Grivaux M, Dore P, Azarian R, Orion B, Boyer J, Raffy O, Jourdain B, Beraud A, Paillot N, Jouveshomme S, Mordacque C, Zureik M, Marsal L, Piquet J, Blanchon F; CPHG. Hôpital Le Raincy-Montfermeil, Paris. T1 tumors have the best prognosis among primary non-small-cell lung cancers, basically because surgery is generally possible. Among patients with primary lung cancer included in the KBP-2000-CPHG study, we examined the characteristics of 419 T1 tumors, i.e. 9.2% of the non-small-cell cancers. Compared with the group of patients with non-t1 tumors, patients with T1 tumors were younger (p=0.0007). They had an equivalent percentage of squamous-cell tumors but more adenocarcinomas (40.3% versus 35.5%, p=0.05). TNM staging showed that 27.6% of the T1 tumors were metastatic at diagnosis (stage IV) with 12.4% T1N0M1 nad 15.2% T1N1-3M1. For the M0 tumors, 52.2% were T1N0 (stage IA) and 20.1% were T1N1-3. Squamous-cell tumors were significantly more frequent among the T1M1 tumors (p=0.07). More than one quarter (27.6%) of the T1 tumors were in stage IV, pointing out the importance of the initial work-up. This findings suggests we should revisit strategies in order to take into account new Page 3
4 diagnostic possibilities. Likewise for the therapeutic strategy. Combinations using chemotherapy, surgery and radiotherapy should be better defined for this group of tumors. PMID: [PubMed - indexed for MEDLINE] 6. Lung Cancer Sep;45(3): Lung cancer among women in France. Analysis of the 904 French women with lung cancer included in the KBP-2000-CPHG study of the French College of General Hospital-based Pneumologists (CPHG). Grivaux M, Breton JL, Bombaron P, Kuntz P, Lebas FX, Mehdaoui A, Herman D, David P, Berruchon J, Delclaux B, Zureik M, Blanchon F; French College of General Hospital-based Pneumologists. Department of Pneumology, Meaux Hospital, 6-8, rue Saint Fiacre, BP 218, Meaux cedex, France. m-grivaux@ch-meaux.fr As the incidence of primary lung cancer in women seems to be increasing in parallel with that of smoking, we conducted an exhaustive epidemiological study in 137 hospitals in We identified 904 women with proven primary lung cancer (mean age 63.9 years), many of whom have never smoked (32.3%), particularly in cases of adenocarcinoma (43.4%). Small cell cancer accounted for 16.1% of cases. Adenocarcinomas were the most frequent (45.3%) of the non-small cell lung cancer (NSCLC), followed by squamous cell (23.4%), large cell (11.6%) and bronchoalveolar (1.9%) carcinomas. About one third (32.2%) of NSCLC were stage III and 48.1% were stage IV. Over half of all adenocarcinomas were stage IV. According to multivariate analysis, adenocarcinoma is related to less smoking and younger age. In conclusion, many women affected by lung cancer have never smoked. Adenocarcinoma appears to be the most frequent form and more often at a metastatic stage. PMID: [PubMed - indexed for MEDLINE] 7. Rev Pneumol Clin Nov;59(5 Pt 2):S56-8. [Lung cancer among French women in 2000: results of an epidemiological study (KBP-2000)] Blanchon F, Grivaux M, Breton JL. Service de Pneumologie, CHG de Meaux, 6, rue Saint-Fiacre, Meaux. PMID: [PubMed - indexed for MEDLINE] 8. Rev Mal Respir Nov;20(5 Pt 1): [Primary bronchial carcinoma in elderly subjects in France] Piquet J, Blanchon F, Grivaux M, Collon T, Zureik M, Barbieux H, Bénichou-Flurin M, Breton JL, Coëtmeur D, Delclaux B, Braun D, Homasson JP, Mouysset F, Riou R, le Poulain-Doubliez M, Marsal L; CPHG. Page 4
5 Hôpital, Le Raincy-Montfermeil, France. INTRODUCTION: There are few data on primary bronchial carcinoma in France. We report here the results of the study KBP 2000-CPHG in which there were 1868 patients aged 70 or more and 338 aged 80 or more. METHODS: We compared the patients under 70 (Group I) with those aged 70 or more (Group II) as well as with the details of the over 80's. RESULTS: Group II included significantly more women (17.4% vs 15.2%; p=0.04), non-smokers (11.2% vs 5.3%; p<0.0001), patients of poor performance status (24.2% vs 14.5%; p<0.0001) and squamous carcinomas (44.5% vs 37.8%; p<0.001) than Group I, but fewer adenocarcinomas (27.2% vs 31.5%; p=0.009) and as many small cell carcinomas (15.9% vs 16.9%; p=0.32). In Group II there were less stage III and IV tumours (75.1% vs 78.1%; p=0.0005) more symptomatic treatment (23.2% vs 6.1%) and radiotherapy alone (12.8% vs 3.8%; p<0.0001). The results were similar beyond 80 years. On multivariate analysis age, performance status and stage appeared to be independent variables in the choice of curative or symptomatic treatment. CONCLUSIONS: Age alone is not therefore a limiting factor in the choice of treatment. PMID: [PubMed - indexed for MEDLINE] 9. Rev Mal Respir Dec;19(6): [Epidemiologic of primary bronchial carcinoma management in the general French hospital centers] Blanchon F, Grivaux M, Collon T, Zureik M, Barbieux H, Bénichou-Flurin M, Breton JL, Coëtmeur D, Delclaux B, Asselain B, Piquet J. Hôpital de Meaux, Paris. f-blanchon@ch-meaux.fr INTRODUCTION: The College of General Hospital Respiratory Physicians have conducted a study aimed at a better understanding of the details and modalities of management of patients suffering from bronchial carcinoma in general hospitals in France. MATERIALS AND METHODS: A prospective epidemiological study was carried out on all the new cases of histologically proven bronchial carcinoma seen in general hospitals in the year The data were collected by a standardised questionnaire. RESULTS: 137 centres of investigation identified patients, mean age 64.3 years, of whom 16% were women. 7.2% of patients were non smokers (with an incidence of 32.3% non-smokers among the women) and 40.3% were ex-smokers. Histologically 16.9% were small cell carcinomas, 40% squamous carcinomas (43.1% among the men, 23.4% among the women, p<0.0001), 30.1% adenocarcinomas (27.2% among the men, 45.3% among the women, p<0.0001). 77.1% of non small cell carcinomas were stages III and IV, and 66.8% of small cell carcinomas were disseminated, with no difference between the sexes. CONCLUSION: Respiratory physicians in general hospitals manage more than a quarter of the cases of bronchial carcinoma seen annually in France. The number of women affected is high with a significant percentage of non-smokers and adenocarcinomas. PMID: [PubMed - indexed for MEDLINE] Page 5
The legally binding text is the original French version TRANSPARENCY COMMITTEE OPINION. 6 June 2012
The legally binding text is the original French version TRANSPARENCY COMMITTEE OPINION 6 June 2012 TARCEVA 25 mg, film-coated tablet B/30 (CIP code: 369 232 3) TARCEVA 100 mg, film-coated tablet B/30 (CIP
More informationAlthough the international TNM classification system
Prognostic Significance of Perioperative Serum Carcinoembryonic Antigen in Non-Small Cell Lung Cancer: Analysis of 1,000 Consecutive Resections for Clinical Stage I Disease Morihito Okada, MD, PhD, Wataru
More informationRatio of maximum standardized uptake value to primary tumor size is a prognostic factor in patients with advanced non-small cell lung cancer
Original Article Ratio of maximum standardized uptake value to primary tumor size is a prognostic factor in patients with advanced non-small cell lung cancer Fangfang Chen 1 *, Yanwen Yao 2 *, Chunyan
More informationNanda Horeweg, Carlijn M. van der Aalst, Erik Thunnissen, Kristiaan Nackaerts, Carla Weenink, Harry J.M. Groen, Jan-Willem J.
Characteristics of lung cancers detected in the randomized NELSON lung cancer screening trial Nanda Horeweg, Carlijn M. van der Aalst, Erik Thunnissen, Kristiaan Nackaerts, Carla Weenink, Harry J.M. Groen,
More informationRelevance of an extensive follow-up after surgery for nonsmall cell lung cancer
ORIGINAL ARTICLE LUNG CANCER Relevance of an extensive follow-up after surgery for nonsmall cell lung cancer Delphine Gourcerol 1,2, Arnaud Scherpereel 1,2, Stephane Debeugny 3, Henri Porte 2,4, Alexis
More informationTreatment of oligometastatic NSCLC
Treatment of oligometastatic NSCLC Jarosław Kużdżał Department of Thoracic Surgery Jagiellonian University Collegium Medicum, John Paul II Hospital, Cracow New idea? 14 NSCLC patients with solitary extrathoracic
More informationNew insights into stage and prognosis in small cell lung cancer: an analysis of 968 cases
Original Article New insights into stage and prognosis in small cell lung cancer: an analysis of 968 cases Charles Dayen 1, Didier Debieuvre 2, Olivier Molinier 3, Olivier Raffy 4, Fabrice Paganin 5, Jérôme
More informationRevisit of Primary Malignant Neoplasms of the Trachea: Clinical Characteristics and Survival Analysis
Jpn J Clin Oncol 1997;27(5)305 309 Revisit of Primary Malignant Neoplasms of the Trachea: Clinical Characteristics and Survival Analysis -, -, - - 1 Chest Department and 2 Section of Thoracic Surgery,
More informationTemporal Trends in Demographics and Overall Survival of Non Small-Cell Lung Cancer Patients at Moffitt Cancer Center From 1986 to 2008
Special Report Temporal Trends in Demographics and Overall Survival of Non Small-Cell Lung Cancer Patients at Moffitt Cancer Center From 1986 to 2008 Matthew B. Schabath, PhD, Zachary J. Thompson, PhD,
More informationPrevalence and associated factors for non-resectable lung cancer at presentation
Prevalence and associated factors for non-resectable lung cancer at presentation 1 Che Wan A. Hashim, 2 Azza Omar, 3 Shaharudin Abdullah, 4 T. Alina T Ismail 1,2,3 Department of Medicine and 4 Department
More informationThe legally binding text is the original French version TRANSPARENCY COMMITTEE OPINION. 14 May 2008
Page 1 The legally binding text is the original French version TRANSPARENCY COMMITTEE OPINION 14 May 2008 AVASTIN 25 mg/ml Pack of 1 vial containing 4 ml (CIP: 566 200-7) Pack of 1 vial containing 16 ml
More informationLONDON CANCER NEW DRUGS GROUP RAPID REVIEW. Erlotinib for the third or fourth-line treatment of NSCLC January 2012
Disease background LONDON CANCER NEW DRUGS GROUP RAPID REVIEW Erlotinib for the third or fourth-line treatment of NSCLC January 2012 Lung cancer is the second most common cancer in the UK (after breast),
More informationLung cancer is a major cause of cancer deaths worldwide.
ORIGINAL ARTICLE Prognostic Factors in 3315 Completely Resected Cases of Clinical Stage I Non-small Cell Lung Cancer in Japan Teruaki Koike, MD,* Ryosuke Tsuchiya, MD, Tomoyuki Goya, MD, Yasunori Sohara,
More informationLung cancer treatment outcomes in recipients of lung transplant
Washington University School of Medicine Digital Commons@Becker Open Access Publications 2015 Lung cancer treatment outcomes in recipients of lung transplant Lingling Du Washington University School of
More informationThoracic and head/neck oncology new developments
Thoracic and head/neck oncology new developments Goh Boon Cher Department of Hematology-Oncology National University Cancer Institute of Singapore Research Clinical Care Education Scope Lung cancer Screening
More informationClinicopathological and Survival Pattern in Lung Cancer Patients of Different Age Group
International Journal of Clinical Oncology and Cancer Research 2018; 3(3): 25-29 http://www.sciencepublishinggroup.com/j/ijcocr doi: 10.11648/j.ijcocr.20180303.12 Clinicopathological and Survival Pattern
More informationRESEARCH ARTICLE. Kuanoon Boupaijit, Prapaporn Suprasert* Abstract. Introduction. Materials and Methods
RESEARCH ARTICLE Survival Outcomes of Advanced and Recurrent Cervical Cancer Patients Treated with Chemotherapy: Experience of Northern Tertiary Care Hospital in Thailand Kuanoon Boupaijit, Prapaporn Suprasert*
More informationDiscrimination of Clinical Stages in Lung Cancer Patients by Serum HSP27 and HSP70
Discrimination of Clinical Stages in Lung Cancer Patients by Serum HSP27 and HSP70 Diplomarbeit Zimmermann Matthias ausgeführt an der Universitätsklinik für Chirurgie Christian Doppler Laboratory for Cardiac
More informationLung cancer is one of the most common and most. Delays in the Diagnosis and Treatment of Lung Cancer*
Delays in the Diagnosis and Treatment of Lung Cancer* Eija-Riitta Salomaa, MD, PhD; Susanna Sällinen, BM; Heikki Hiekkanen, MSc; and Kari Liippo, MD, PhD Study objectives: This study was undertaken to
More informationAdjuvant Chemotherapy
State-of-the-art: standard of care for resectable NSCLC Adjuvant Chemotherapy JY DOUILLARD MD PhD Professor of Medical Oncology Integrated Centers of Oncology R Gauducheau University of Nantes France Adjuvant
More informationPalliative radiotherapy near the end of life for brain metastases from lung cancer: a populationbased
Palliative radiotherapy near the end of life for brain metastases from lung cancer: a populationbased analysis Roel Schlijper Fellow Radiation Oncology BC Cancer, Prince George Disclosures No conflicts
More informationMarcel Th. M. van Rens, MD; Aart Brutel de la Rivière, MD, PhD, FCCP; Hans R. J. Elbers, MD, PhD; and Jules M. M. van den Bosch, MD, PhD, FCCP
Prognostic Assessment of 2,361 Patients Who Underwent Pulmonary Resection for Non-small Cell Lung Cancer, Stage I, II, and IIIA* Marcel Th. M. van Rens, MD; Aart Brutel de la Rivière, MD, PhD, FCCP; Hans
More informationRelevance of an Intensive Postoperative Follow-up After Surgery for Non Small Cell Lung Cancer
Relevance of an Intensive Postoperative Follow-up After Surgery for Non Small Cell Lung Cancer Virginie Westeel, MD, Didier Choma, MD, François Clément, MD, Marie-Christine Woronoff-Lemsi, PhD, Jean-François
More informationPrognostic factors in squamous cell anal cancers
Prognostic factors in squamous cell anal cancers Zainul Abedin Kapacee Year 4-5 Intercalating Medical Student, University of Manchester Dr. Shabbir Susnerwala, Mr. Nigel Scott Dr. Falalu Danwata, Dr. Marcus
More informationIntegration of Palliative and Oncology Care in patients with lung and other
1 Integration of Palliative and Oncology Care in patients with lung and other thoracic cancer: referral criteria and clinical care pathways. A. Caraceni, C. Brunelli, S. Lo Dico, E. Zecca, P. Bracchi,
More informationDiagnosis and Staging of Non-Small Cell Lung Cancer Carlos Eduardo Oliveira Baleeiro, MD. November 18, 2017
Diagnosis and Staging of Non-Small Cell Lung Cancer Carlos Eduardo Oliveira Baleeiro, MD November 18, 2017 Disclosures I do not have a financial interest/arrangement or affiliation with one or more organizations
More informationThere has been a growing interest in lung cancer in neversmokers,
ORIGINAL ARTICLE,, and Time of Diagnosis Are Important Factors for Prognosis Analysis of 1499 Never-Smokers with Advanced Non-small Cell Lung Cancer in Japan Tomoya Kawaguchi, MD,* Minoru Takada, MD,*
More informationStage 4 adenocarcinoma lung cancer icd 10
Stage 4 adenocarcinoma lung cancer icd 10 2018 ICD-10-CM Index 'A' Terms Adenocarcinoma - see also Neoplasm, malignant, by site. acidophil. specified. ICD-10-CM Diagnosis Code C25. 4. Lung adenocarcinoma
More informationThe role of cytoreductive. nephrectomy in elderly patients. with metastatic renal cell. carcinoma in an era of targeted. therapy
The role of cytoreductive nephrectomy in elderly patients with metastatic renal cell carcinoma in an era of targeted therapy Dipesh Uprety, MD Amir Bista, MD Yazhini Vallatharasu, MD Angela Smith, MA David
More informationCorrelation of pretreatment surgical staging and PET SUV(max) with outcomes in NSCLC. Giancarlo Moscol, MD PGY-5 Hematology-Oncology UTSW
Correlation of pretreatment surgical staging and PET SUV(max) with outcomes in NSCLC Giancarlo Moscol, MD PGY-5 Hematology-Oncology UTSW BACKGROUND AJCC staging 1 gives valuable prognostic information,
More informationIn 1989, Deslauriers et al. 1 described intrapulmonary metastasis
ORIGINAL ARTICLE Prognosis of Resected Non-Small Cell Lung Cancer Patients with Intrapulmonary Metastases Kanji Nagai, MD,* Yasunori Sohara, MD, Ryosuke Tsuchiya, MD, Tomoyuki Goya, MD, and Etsuo Miyaoka,
More informationAccepted Manuscript. Risk stratification for distant recurrence of resected early stage NSCLC is under construction. Michael Lanuti, MD
Accepted Manuscript Risk stratification for distant recurrence of resected early stage NSCLC is under construction Michael Lanuti, MD PII: S0022-5223(17)32392-9 DOI: 10.1016/j.jtcvs.2017.10.063 Reference:
More informationSurvival Prediction Models for Estimating the Benefit of Post-Operative Radiation Therapy for Gallbladder Cancer and Lung Cancer
Survival Prediction Models for Estimating the Benefit of Post-Operative Radiation Therapy for Gallbladder Cancer and Lung Cancer Jayashree Kalpathy-Cramer PhD 1, William Hersh, MD 1, Jong Song Kim, PhD
More informationNon-small Cell Lung Cancer in the Young: A Retrospective Analysis of Diagnosis, Management and Outcome Data
ANTICANCER RESECH 26: 3175-3182 (2006) Non-small Cell Lung Cancer in the Young: A Retrospective Analysis of Diagnosis, Management and Outcome Data D. MAURI, G. PENTHEROUDAKIS, D. BAFALOUKOS, D. PECTASIDES,
More informationPrognostic value of visceral pleura invasion in non-small cell lung cancer q
European Journal of Cardio-thoracic Surgery 23 (2003) 865 869 www.elsevier.com/locate/ejcts Prognostic value of visceral pleura invasion in non-small cell lung cancer q Jeong-Han Kang, Kil Dong Kim, Kyung
More informationOnly Estrogen receptor positive is not enough to predict the prognosis of breast cancer
Young Investigator Award, Global Breast Cancer Conference 2018 Only Estrogen receptor positive is not enough to predict the prognosis of breast cancer ㅑ Running head: Revisiting estrogen positive tumors
More informationUpdates on the Conflict of Postoperative Radiotherapy Impact on Survival of Young Women with Cancer Breast: A Retrospective Cohort Study
International Journal of Medical Research & Health Sciences Available online at www.ijmrhs.com ISSN No: 2319-5886 International Journal of Medical Research & Health Sciences, 2017, 6(7): 14-18 I J M R
More informationOUR EXPERIENCES WITH ERLOTINIB IN SECOND AND THIRD LINE TREATMENT PATIENTS WITH ADVANCED STAGE IIIB/ IV NON-SMALL CELL LUNG CANCER
& OUR EXPERIENCES WITH ERLOTINIB IN SECOND AND THIRD LINE TREATMENT PATIENTS WITH ADVANCED STAGE IIIB/ IV NON-SMALL CELL LUNG CANCER Interim Data Report of TRUST study on patients from Bosnia and Herzegovina
More informationEpidemiology, aetiology and the patient pathway in oesophageal and pancreatic cancers
Epidemiology, aetiology and the patient pathway in oesophageal and pancreatic cancers Dr Ian Chau Consultant Medical Oncologist Women's cancers Breast cancer introduction 3 What profession are you in?
More informationTreatment of EGFR mutant advanced NSCLC
Treatment of EGFR mutant advanced NSCLC Raffaele Califano Department of Medical Oncology The Christie and University Hospital of South Manchester, Manchester, UK Outline Data on first-line Overcoming T790M
More informationWhat is New in Geriatric Oncology: The Medical Oncology Perspective. Arti Hurria, MD Director, Cancer and Aging Research Program City of Hope
What is New in Geriatric Oncology: The Medical Oncology Perspective Arti Hurria, MD Director, Cancer and Aging Research Program City of Hope Cancer Incidence in the U.S. Between 2010 and 2030, cancer incidence
More informationCauses of Treatment Failure and Death in Carcinoma of the Lung
THE YALE JOURNAL OF BIOLOGY AND MEDICINE 54 (1981), 201-207 Causes of Treatment Failure and Death in Carcinoma of the Lung JAMES D. COX, M.D.,a AND RAYMOND A. YESNER, M.D.b The Medical College of Wisconsin,
More informationHYPERTHERMIA in CERVIX and VAGINA CANCER. J. van der Zee
HYPERTHERMIA in CERVIX and VAGINA CANCER J. van der Zee ESTRO 2006 Deep hyperthermia in Rotterdam HYPERTHERMIA in CERVIX and VAGINA CANCER ESTRO 2006 Hyperthermia and radiotherapy in primary advanced cervix
More informationInteraction between treatment delivery delay and stage on the mortality from non-small cell lung cancer
Original Article Interaction between treatment delivery delay and stage on the mortality from non-small cell lung cancer Fernando Conrado Abrao 1,2, Igor Renato Louro Bruno de Abreu 1,2, Roberto Odebrecht
More informationClinicopathological Factors Affecting Distant Metastasis Following Loco-Regional Recurrence of breast cancer. Cheol Min Kang 2018/04/05
Abstract No.: ABS-0075 Clinicopathological Factors Affecting Distant Metastasis Following Loco-Regional Recurrence of breast cancer 2018/04/05 Cheol Min Kang Department of surgery, University of Ulsan
More informationPrognostic Factors for Survival of Stage IB Upper Lobe Non-small Cell Lung Cancer Patients: A Retrospective Study in Shanghai, China
www.springerlink.com Chin J Cancer Res 23(4):265 270, 2011 265 Original Article Prognostic Factors for Survival of Stage IB Upper Lobe Non-small Cell Lung Cancer Patients: A Retrospective Study in Shanghai,
More informationResearch Article Prognostic Factors in Advanced Non-Small-Cell Lung Cancer Patients: Patient Characteristics and Type of Chemotherapy
SAGE-Hindawi Access to Research Lung Cancer International Volume 2011, Article ID 152125, 4 pages doi:10.4061/2011/152125 Research Article Prognostic Factors in Advanced Non-Small-Cell Lung Cancer Patients:
More informationAdvances in gastric cancer: How to approach localised disease?
Advances in gastric cancer: How to approach localised disease? Andrés Cervantes Professor of Medicine Classical approach to localised gastric cancer Surgical resection Pathology assessment and estimation
More informationRare Small Cell Carcinoma in Genitourinary Tract: Experience from E-Da Hospital
E-Da Medical Journal 20;():-5 Original Article Rare Small Cell Carcinoma in Genitourinary Tract: Experience from E-Da Hospital Wei-Ting Kuo, I-Wei Chang2, Kevin Lu, Hua-Pin Wang, Tsan-Jung u, Victor C.
More information8th Edition of the TNM Classification for Lung Cancer. Proposed by the IASLC
8th Edition of the TNM Classification for Lung Cancer Proposed by the IASLC Introduction Stage classification - provides consistency in nomenclature - improves understanding of anatomic extent of tumour
More informationIs Bevacizumab (Avastin) Safe and Effective as Adjuvant Chemotherapy for Adult Patients With Stage IIIb or IV Non-Small Cell Lung Carcinoma (NSCLC)?
Philadelphia College of Osteopathic Medicine DigitalCommons@PCOM PCOM Physician Assistant Studies Student Scholarship Student Dissertations, Theses and Papers 2014 Is Bevacizumab (Avastin) Safe and Effective
More informationSurveillance following treatment of primary ocular melanoma
Surveillance following treatment of primary ocular melanoma Introduction 50% of UM patients relapse with predominantly liver metastases Risk of metastatic disease can be predicted relatively accurately
More informationHyponatremia in small cell lung cancer is associated with a poorer prognosis
Original Article Hyponatremia in small cell lung cancer is associated with a poorer prognosis Wenxian Wang 1, Zhengbo Song 1,2, Yiping Zhang 1,2 1 Department of Chemotherapy, Zhejiang Cancer Hospital,
More informationNumber of Metastatic Lymph Nodes in Resected Non Small Cell Lung Cancer Predicts Patient Survival
Number of Metastatic Lymph Nodes in Resected Non Small Cell Lung Cancer Predicts Patient Survival Jin Gu Lee, MD, Chang Young Lee, MD, In Kyu Park, MD, Dae Joon Kim, MD, Seong Yong Park, MD, Kil Dong Kim,
More informationCervical cancer presentation
Carcinoma of the cervix: Carcinoma of the cervix is the second commonest cancer among women worldwide, with only breast cancer occurring more commonly. Worldwide, cervical cancer accounts for about 500,000
More informationRevisiting Stage IIIB and IV Non-small Cell Lung Cancer. Analysis of the Surveillance, Epidemiology, and End Results Data
CHEST Revisiting Stage IIIB and IV Non-small Cell Lung Cancer Analysis of the Surveillance, Epidemiology, and End Results Data William N. William, Jr, MD; Heather Y. Lin, PhD; J. Jack Lee, PhD; Scott M.
More informationCharles Mulligan, MD, FACS, FCCP 26 March 2015
Charles Mulligan, MD, FACS, FCCP 26 March 2015 Review lung cancer statistics Review the risk factors Discuss presentation and staging Discuss treatment options and outcomes Discuss the status of screening
More informationPulmonary resection remains the most effective. Survival in Synchronous vs Single Lung Cancer. Upstaging Better Reflects Prognosis
Survival in Synchronous vs Single Lung Cancer Upstaging Better Reflects Prognosis Marcel Th. M. van Rens, MD; Pieter Zanen, MD, PhD; Aart Brutel de la Rivière, MD, PhD, FCCP; Hans R. J. Elbers, MD, PhD;
More informationComorbidities and cancer Applications to non small cell lung cancer
Comorbidities and cancer Applications to non small cell lung cancer Pr A. Vergnenègre Dr H. Le Caer CHU Limoges CH Draguignan 1 Comorbidities and cancer Why? 2 Epidemiology elderly among lung cancer 2010-2014
More informationClinical significance of skipping mediastinal lymph node metastasis in N2 non-small cell lung cancer
Original Article Clinical significance of skipping mediastinal lymph node metastasis in N2 non-small cell lung cancer Jun Zhao*, Jiagen Li*, Ning Li, Shugeng Gao Department of Thoracic Surgery, National
More informationNon-small Cell Lung Cancer: Multidisciplinary Role: Role of Medical Oncologist
Non-small Cell Lung Cancer: Multidisciplinary Role: Role of Medical Oncologist Vichien Srimuninnimit, MD. Medical Oncology Division Faculty of Medicine, Siriraj Hospital Outline Resectable NSCLC stage
More informationStage 1 esophageal cancer survival rate
Stage 1 esophageal cancer survival rate Search Below are the five-year survival rates for esophageal cancer patients treated by SCCA compared to patients who were treated for esophageal. Stage I Esophageal
More informationSponsor / Company: Sanofi Drug substance(s): Docetaxel (Taxotere )
These results are supplied for informational purposes only. Prescribing decisions should be made based on the approved package insert in the country of prescription. Sponsor / Company: Sanofi Drug substance(s):
More informationExtent of visceral pleural invasion and the prognosis of surgically resected node-negative non-small cell lung cancer
Thoracic Cancer ISSN 1759-7706 ORIGINAL ARTICLE Extent of visceral pleural invasion and the prognosis of surgically resected node-negative non-small cell lung cancer Yangki Seok 1, Ji Yun Jeong 2 & Eungbae
More informationTreatment of EGFR mutant advanced NSCLC
Treatment of EGFR mutant advanced NSCLC Raffaele Califano Department of Medical Oncology The Christie and Manchester University Hospital Manchester, UK Outline Data on first-line Overcoming T790M mutation
More informationOncologist. The. Symptom Management and Supportive Care
The Oncologist Symptom Management and Supportive Care Does Marital Status Impact Survival and Quality of Life in Patients with Non-Small Cell Lung Cancer? Observations from the Mayo Clinic Lung Cancer
More informationSurgical resection improves survival in pancreatic cancer patients without vascular invasion- a population based study
Original article Annals of Gastroenterology (2013) 26, 346-352 Surgical resection improves survival in pancreatic cancer patients without vascular invasion- a population based study Subhankar Chakraborty
More informationAuthor's response to reviews
Author's response to reviews Title: Brain metastasis development and poor survival associated with carcinoembryonic antigen (CEA) level in advanced non-small cell lung cancer: a prospective analysis Authors:
More informationRisk group criteria for tailoring adjuvant treatment in patients with endometrial cancer : a validation study of the GOG criteria
Risk group criteria for tailoring adjuvant treatment in patients with endometrial cancer : a validation study of the GOG criteria Suk-Joon Chang, MD, Hee-Sug Ryu MD Gynecologic Cancer Center Department
More informationfollowing radiotherapy
British Journal of Cancer (1995) 72, 1536-154 r) 1995 Stockton Press All rights reserved 7-92/95 $12. Serum tumour markers in carcinoma of the uterine cervix and outcome following radiotherapy ARM Sproston',
More informationExpression of programmed death ligand-1 on tumor cells varies pre and post
Expression of programmed death ligand-1 on tumor cells varies pre and post chemotherapy in non-small cell lung cancer Jin Sheng 1,2,3,*, Wenfeng Fang 1,2,3,*, Juan Yu 3, Yunpeng Yang 1,2,3, Yuxiang Ma
More informationLUNG CANCER. Agnieszka Słowik, MD. Department of Oncology, University Hospital in Cracow Jagiellonian University
LUNG CANCER Agnieszka Słowik, MD Department of Oncology, University Hospital in Cracow Jagiellonian University Epidemiology Most common malignancy worldwide Place of lung cancer among other malignancies
More informationLUNG CANCER PATHOLOGY: UPDATE ON NEUROENDOCRINE LUNG TUMORS
LUNG CANCER PATHOLOGY: UPDATE ON NEUROENDOCRINE LUNG TUMORS William D. Travis, M.D. Attending Thoracic Pathologist Memorial Sloan Kettering Cancer Center New York, NY PULMONARY NE TUMORS CLASSIFICATION
More informationDescriptor Definition Author s notes TNM descriptors Required only if applicable; select all that apply multiple foci of invasive carcinoma
S5.01 The tumour stage and stage grouping must be recorded to the extent possible, based on the AJCC Cancer Staging Manual (7 th Edition). 11 (See Tables S5.01a and S5.01b below.) Table S5.01a AJCC breast
More informationThe Evolving Role of Adjuvant Therapies
Therapy-predictive markers for adjuvant chemotherapy The Evolving Role of Adjuvant Therapies Micrometastasis Prognostic Markers (BRCA1) Cured No Further Tx Chemosensitive Rafael Rosell th European Perspectives
More informationThe 7th Edition of TNM in Lung Cancer.
10th European Conference Perspectives in Lung Cancer. Brussels, March 2009. The 7th Edition of TNM in Lung Cancer. Peter Goldstraw, Consultant Thoracic Surgeon, Royal Brompton Hospital, Professor of Thoracic
More informationEndobronchial Ultrasound in the Diagnosis & Staging of Lung Cancer
Endobronchial Ultrasound in the Diagnosis & Staging of Lung Cancer Dr Richard Booton PhD FRCP Lead Lung Cancer Clinician, Consultant Respiratory Physician & Speciality Director Manchester University NHS
More informationHot topics in Radiation Oncology for the Primary Care Providers
Hot topics in Radiation Oncology for the Primary Care Providers Steven Feigenberg, MD Professor Chief, Thoracic Oncology Vice Chair of Clinical Research April 19, 2018 Disclosures NONE 2 Early Stage Disease
More informationEpidemiology of Meningiomas in England
Epidemiology of Meningiomas in England Tina Karabatsou 1, David Greenberg 2, Sarah Miller 2, Andy Brodbelt 4, Matt Williams 3 & Peter Collins 5 1 Salford Royal Hospital NHS Foundation Trust, Manchester
More informationIs Ovarian Preservation Feasible in Early-Stage Adenocarcinoma of the Cervix?
e-issn 1643-3750 DOI: 10.12659/MSM.897291 Received: 2015.12.27 Accepted: 2016.01.13 Published: 2016.02.08 Is Ovarian Preservation Feasible in Early-Stage Adenocarcinoma of the Cervix? Authors Contribution:
More informationPET/CT in breast cancer staging
PET/CT in breast cancer staging Anni Morsing Consultant, PhD, DMSc Rigshospitalet 1 18F- FDG PET/CT for breastcancer staging Where is the clinical impact? To which women should 18F- FDG PET/CT be offered?
More informationClinical Aspects of SBRT in Abdominal Regions Brian D. Kavanagh, MD, MPH University of Colorado Department of Radiation Oncology
Clinical Aspects of SBRT in Abdominal Regions Brian D. Kavanagh, MD, MPH University of Colorado Department of Radiation Oncology Abdominal SBRT: Clinical Aspects Rationales for liver and pancreas SBRT
More informationNivolumab: esperienze italiane nel carcinoma polmonare avanzato
NSCLC avanzato: quali novità nel 2018? Negrar, 30 Ottobre 2018 Nivolumab: esperienze italiane nel carcinoma polmonare avanzato Francesco Grossi UOC Oncologia Medica Fondazione IRCCS Ca Granda Ospedale
More information3/8/2014. Case Presentation. Primary Treatment of Anal Cancer. Anatomy. Overview. March 6, 2014
Case Presentation Primary Treatment of Anal Cancer 65 year old female presents with perianal pain, lower GI bleeding, and anemia with Hb of 7. On exam 6 cm mass protruding through the anus with bulky R
More informationLong-Term Outcome and Late Recurrence in Patients with Completely Resected Stage IA Non-small Cell Lung Cancer
ORIGINAL ARTICLE Long-Term Outcome and Late Recurrence in Patients with Completely Resected Stage IA Non-small Cell Lung Cancer Ryo Maeda, MD,* Junji Yoshida, MD,* Genichiro Ishii, MD, Keiju Aokage, MD,*
More informationSlide 1. Slide 2. Slide 3. Investigation and management of lung cancer Robert Rintoul. Epidemiology. Risk factors/aetiology
Slide 1 Investigation and management of lung cancer Robert Rintoul Department of Thoracic Oncology Papworth Hospital Slide 2 Epidemiology Second most common cancer in the UK (after breast). 38 000 new
More informationThe 8th Edition of the TNM Classification for Lung Cancer Background, Innovations and Implications for Clinical Practice
The 8th Edition of the TNM Classification for Lung Cancer Background, Innovations and Implications for Clinical Practice University of Torino Lecture 28th June 2017 Torino, Italy Ramón Rami-Porta Thoracic
More informationMolly Boyd, MD Glenn Mills, MD Syed Jafri, MD 1/1/2010
LSU HEALTH SCIENCES CENTER NSCLC Guidelines Feist-Weiller Cancer Center Molly Boyd, MD Glenn Mills, MD Syed Jafri, MD 1/1/2010 Initial Evaluation/Intervention: 1. Pathology Review 2. History and Physical
More informationTRANSPARENCY COMMITTEE OPINION. 29 April 2009
The legally binding text is the original French version TRANSPARENCY COMMITTEE OPINION 29 April 2009 NAVELBINE 20 mg, soft capsules B/1 (CIP: 365 948-4) NAVELBINE 30 mg, soft capsules B/1 (CIP: 365 949-0)
More informationCan erythropoietin treatment during antiviral drug treatment for hepatitis C be cost effective?
Below Are Selected Good Abstracts from Digestive Disease Week 2006 Meeting Published in Gut. 2006 April; 55(Suppl 2): A1 A119. http://www.ncbi.nlm.nih.gov/pmc/articles/pmc1859999/?tool=pmcentrez Can erythropoietin
More informationMetastatic NSCLC: Expanding Role of Immunotherapy. Evan W. Alley, MD, PhD Abramson Cancer Center at Penn Presbyterian
Metastatic NSCLC: Expanding Role of Immunotherapy Evan W. Alley, MD, PhD Abramson Cancer Center at Penn Presbyterian Disclosures: No relevant disclosures Please note that some of the studies reported in
More informationLara Kujtan, MD; Abdulraheem Qasem, MD
The Treatment of Lung Cancer Between 2013-2014 at Truman Medical Center: A Retrospective Review in Fulfillment of the Requirements of Standard 4.6 (Monitoring Compliance with Evidence- Based Guidelines)
More informationApplying Genomics to Cancer 21 st September The Frequency of EGFR mutations in Lung Adenocarcinoma: The Cardiff Experience
Applying Genomics to Cancer 21 st September 2015 The Frequency of EGFR mutations in Lung Adenocarcinoma: The Cardiff Experience Aled Daniels R Butler, R Attanoos, H Davies University Hospital of Wales
More informationAfter primary tumor treatment, 30% of patients with malignant
ESTS METASTASECTOMY SUPPLEMENT Alberto Oliaro, MD, Pier L. Filosso, MD, Maria C. Bruna, MD, Claudio Mossetti, MD, and Enrico Ruffini, MD Abstract: After primary tumor treatment, 30% of patients with malignant
More informationAudit Report. Lung Cancer Quality Performance Indicators. Patients diagnosed January December Published: November 2017
Lung Cancer Managed Clinical Network Audit Report Lung Cancer Quality Performance Indicators Patients diagnosed January December 2016 Published: November 2017 Hardy Remmen NOSCAN Lung Cancer MCN Clinical
More informationFUJI study: Follow-Up of Jevtana in real life
Pharmacologie médicale Bordeaux PharmacoEpi CIC Bordeaux CIC1401 FUJI study: Follow-Up of Jevtana in real life English version of the synopsis Version 2.0: 24 June 2016 EU PAS register: ENCEPP/SDPP/10391
More informationONCOLOGY LETTERS 8: , 2014
ONCOLOGY LETTERS 8: 813-818, 2014 Investigation of the epidermal growth factor receptor mutation rate in non small cell lung cancer patients and the analysis of associated risk factors using logistic regression
More informationMATERIALS AND METHODS
Primary Triple Androgen Blockade (TAB) followed by Finasteride Maintenance (FM) for clinically localized prostate cancer (CL-PC): Long term follow-up and quality of life (QOL) SJ Tucker, JN Roundy, RL
More informationEnrollment Form: Pancreas
Tissue Source Site (TSS) Name: TSS Identifier: _ TSS Unique Patient #: Completed By: Completion Date (MM/DD/YYYY): Form Notes: An Enrollment Form should be completed for each TCGA qualified case upon qualification
More informationEGFR inhibitors in NSCLC
Suresh S. Ramalingam, MD Associate Professor Director of Medical Oncology Emory University i Winship Cancer Institute EGFR inhibitors in NSCLC Role in 2nd/3 rd line setting Role in first-line and maintenance
More information